Press "Enter" to skip to content

Gilead’s Remdesivir delivers ‘rapid recoveries’


CLOSE

Coronavirus patients around the world have been rushing to join remdesivir studies that opened in hospitals in the last few weeks. (April 6)

AP Domestic

A Gilead Sciences antiviral drug is reportedly showing promise for treatment of the coronavirus.

Remdesivir is causing “rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week” in patients at a Chicago hospital, medical site STAT reported.

The story has led to a surge in stock futures Friday and a jump in Gilead’s stock price, which rose 10.8% in pre-market trading to $84.80.

“The entire world has been waiting for results from Gilead’s clinical trials, and positive results would likely lead to fast approvals by the Food and Drug Administration and other regulatory agencies,” STAT reported. “If safe and effective, it could become the first approved treatment against the disease.”

Remdesivir is one of numerous drugs under development to treat or cure the coronavirus. Clinical trials are conducted to ensure safety and efficacy, and there’s no guarantee the Chicago hospital’s results will be replicated elsewhere.

CLOSE

The coronavirus is causing major stresses in households. Here’s a look at how the country is doing and tips on how to cope with mental health issues.

USA TODAY

The results came from the University of Chicago Medicine, which is participating in two Gilead clinical trials involving 2,400 severe cases at 152 sites and 1,600 moderate cases at 169 sites, according to STAT. The University of Chicago data covered 125 people infected with COVID-19, including 113 severe cases, all of whom are being given daily doses.

STAT reported the news based on a video of trial leaders discussing the early results.

Meat shortage 2020:: Coronavirus has led Smithfield, other plants to close, farmers to dump milk

Coronavirus auto insurance refunds: Here’s what you need to know

Evercore ISI drug industry analyst Umer Raffat wrote late Thursday in a research note that it’s “not a silver bullet” but there’s reason to be “cautiously optimistic.”

Medical professionals have had high hopes for remdesivir since the coronavirus pandemic began.

Other studies have shown promising results, as well, albeit with fewer patients.

The New England Journal of Medicine on Friday published the results of a 10-day study involving 53 “quite severe” patients in which 68% showed “clinical improvement,” 47% were discharged before the study was completed and 13% died, according to UBS analyst Navin Jacob.

“Ultimately if remdesivir does prove effective, we think it is likely to be best suited for treating hospitalized patients and unlikely as a prophylactic therapy given some unknowns on safety,” Jacob wrote Monday in a research note. “Nonetheless an effective treatment that reduces the need for ICU beds, speeds up discharges, & reduces mortality could hypothetically provide relief to the (health care) system.”

Remdesivir, the result of more than a decade of Gilead research, has been tested for multiple potential applications in recent years. The company tested the drug as a treatment for Ebola in west Africa in 2014. It has also been tested as a treatment of SARS and for hepatitis C.

Gilead representatives were not immediately available to comment Friday.

If remdesivir were approved by the FDA, Gilead hopes to start manufacturing quickly.

“In anticipation of potential future needs, we have accelerated manufacturing timelines to increase our available supply as rapidly as possible,” Gilead says in a fact sheet about the drug. “We are doing this before knowing whether remdesivir will be determined to be safe and effective to treat patients with COVID-19.”

Follow USA TODAY reporter Nathan Bomey on Twitter @NathanBomey.

Read or Share this story: https://www.usatoday.com/story/money/2020/04/17/remdesivir-coronavirus-drug-gilead-sciences-covid-19-treatment/5150793002/





Source link

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *